Shareholders Will Probably Not Have Any Issues With Xenon Pharmaceuticals Inc.'s (NASDAQ:XENE) CEO Compensation [Yahoo! Finance]
Xenon Pharmaceuticals Inc. - Common Shares (XENE)
Last xenon pharmaceuticals inc. - common shares earnings: 11/5 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.xenon-pharma.com
Company Research
Source: Yahoo! Finance
The total compensation is similar to the average for the industry Xenon Pharmaceuticals' EPS declined by 28% over the past three years while total shareholder return over the past three years was 109% Despite strong share price growth of 109% for Xenon Pharmaceuticals Inc. NASDAQ:XENE ) over the last few years, earnings growth has been disappointing, which suggests something is amiss. Some of these issues will occupy shareholders' minds as the AGM rolls around on 4th of June. It would also be an opportunity for them to influence management through exercising their voting power on company resolutions, including CEO and executive remuneration, which could impact on firm performance in the future. From what we gathered, we think shareholders should be wary of raising CEO compensation until the company shows some marked improvement. Check out our latest analysis for Xenon Pharmaceuticals Comparing Xenon Pharmaceuticals Inc.'s CEO Compensation With The Industry At the time of wr
Show less
Read more
Impact Snapshot
Event Time:
XENE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
XENE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
XENE alerts
High impacting Xenon Pharmaceuticals Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
XENE
News
- Is Xenon Pharmaceuticals Inc. (XENE) One of the Best Healthcare Stocks Under $50? [Yahoo! Finance]Yahoo! Finance
- Xenon Pharmaceuticals Inc. (NASDAQ: XENE) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $55.00 price target on the stock.MarketBeat
- Xenon Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare ConferenceGlobeNewswire
- Xenon Pharmaceuticals Presents Data from Phase 2 X-NOVA Clinical Trial of Azetukalner in Major Depressive Disorder at the American Society of Clinical Psychopharmacology 2024 Annual Meeting [Financial Post (Toronto, Ontario, Canada)]Financial Post
- Xenon Pharmaceuticals Presents Data from Phase 2 X-NOVA Clinical Trial of Azetukalner in Major Depressive Disorder at the American Society of Clinical Psychopharmacology 2024 Annual Meeting [Yahoo! Finance]Yahoo! Finance
XENE
Earnings
- 5/9/24 - Beat
XENE
Sec Filings
- 6/12/24 - Form 144
- 6/5/24 - Form 4
- 6/5/24 - Form 4
- XENE's page on the SEC website